High-dose darbepoetin therapy in a diabetic kidney disease patient with myelodysplastic syndrome-Reference-Cited by-同舟云学术

High-dose darbepoetin therapy in a diabetic kidney disease patient with myelodysplastic syndrome

Published:2015 Issue:6 Volume:48 Page:365-370
ISSN:1340-3451
Container-title:Nihon Toseki Igakkai Zasshi
language:en
Short-container-title:Nihon Toseki Igakkai Zasshi

Author:

Morita Sayaka¹²,Nyumura Izumi²,Eguchi Kei²,Yamashita Shinpei²,Yoshida Noriko²,Toyonaga Aiko²,Takemura Shunsuke²,Takagi Michino²,Yoshida Naoshi²,Oya Junko²,Hanai Ko²,Tanaka Nobue²,Yoshinaga Kentaro³,Yamada Norihiro⁴,Babazono Tetsuya²,Akiba Takashi⁵,Motoji Toshiko³,Hagiwara Nobuhisa⁴,Fuchinoue Shohei¹,Uchigata Yasuko²

Affiliation:

1. Department of Surgery, Kidney Center

2. Department of Medicine, Diabetes Center

3. Department of Hematology

4. Department of Cardiology

5. Department of Blood Purification, Kidney Center, Tokyo Women’s Medical University School of Medicine

Publisher

Japanese Society for Dialysis Therapy

Subject

Organic Chemistry,Biochemistry

Reference13 articles.

1. 2) National Comprehensive Cancer Network. NCCN Guidelines TM version 2. 2011 updates myelodysplastic syndromes. Archived versions of the guidelines from 2001 and 2006 were obtained from the NCCN.

2. 4) Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594-603.

3. 7) Victor M, Patrick L, Mei SD, Behin Y, Suneel M. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 2008; 87: 527-36.

4. 14) Ohshima M, Ubara Y, Tagami T, et al. Long-term erythropoietin therapy improves response in myelodysplastic syndrome. Ther Apher Dial 2005; 9: 362-6.

5. 15) Steensma DP. Erythropoiesis-stimulating agents are effective in myelodysplastic syndromes, but are they safe? Am J Hematol 2009; 84: 3-5.